{"title":"醋酸Anecortave用于年龄相关性黄斑变性中存在残余外周活动的纤维化病变。","authors":"Tina Aggermann, Paulina Haas, Susanne Binder","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We retrospectively examined the efficacy of a single juxtascleral anecortave acetate depot injection for the treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration in 20 consecutive patients who rejected intravitreal treatment. As a second line-therapy of classic and occult fibrotic lesions with active peripheral zones, anecortave seems to be a vision conserving therapeutic option.</p>","PeriodicalId":8070,"journal":{"name":"Annals of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.\",\"authors\":\"Tina Aggermann, Paulina Haas, Susanne Binder\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We retrospectively examined the efficacy of a single juxtascleral anecortave acetate depot injection for the treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration in 20 consecutive patients who rejected intravitreal treatment. As a second line-therapy of classic and occult fibrotic lesions with active peripheral zones, anecortave seems to be a vision conserving therapeutic option.</p>\",\"PeriodicalId\":8070,\"journal\":{\"name\":\"Annals of ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of ophthalmology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.
We retrospectively examined the efficacy of a single juxtascleral anecortave acetate depot injection for the treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration in 20 consecutive patients who rejected intravitreal treatment. As a second line-therapy of classic and occult fibrotic lesions with active peripheral zones, anecortave seems to be a vision conserving therapeutic option.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
